ArticleFrontiers in immunology2026
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Innovations and Challenges in Syphilis Screening and Prevention Among Men Who Have Sex With Men: A Scoping Review.Sexually transmitted diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Syphilis is a sexually or vertically transmitted disease caused by the infection of Methods: In this study, we successfully constructed a TP0954 mRNA vaccine and confirmed the immunogenicity of the mRNA vaccine in BALB/c mice and New Zealand White (NZW) rabbits. Then the protective immunity was assessed in immunized NZW rabbits. Results: Our mRNA vaccine elicited humoral and cellular immunological responses both in BALB/c mice and NZW rabbits. Moreover, TP0954 mRNA vaccine was more effective in attenuating lesion development compared with TP0954 protein vaccine. Similarly, the Conclusion: Therefore, we successfully constructed a novel mRNA vaccine targeting TP0954 for syphilis and found superior immune protective effects compared with TP0954 recombinant protein vaccine, further confirming that TP0954 is a promising vaccine candidate for syphilis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.